NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

About this update from Nrx Pharmaceuticals, Inc.

[{"type":"text","content":"Company to Host Conference Call and Webcast May 16, 2022, at 8:30am ET\nRADNOR, Pa., May 16, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2022 and provided a business and clinical update.\n\n \n \n \n \n \n \n\n \nNRX-101 Dosed the First Patient in Phase II Study.\"During our first quarter of 2022 we continued to make progress on our strategic priorities for our two key compounds, namely advancing NRX-101 for bipolar depression with Acute and Sub-Acute Suicidal Ideation & Behavior and intravenous ZYESAMI® for COVID-19,\" said Robert Besthof, Interim Chief Executive Officer of NRx Pharmaceuticals.\nCOVID-19 has also significantly affected the mental health status of the United States. \"We have all heard about the recent loss of lives due to suicide of well-known people, and those only known to few. Hence, we are pleased to have restarted development of our psychiatry franchise with the initiation of a Phase II clinical study of NRX-101 for patients with bipolar depression and sub-acute suicidal ideation & behavior (SSIB) for which the first patient was enrolled on May 12, 2022,\" continued Mr. Besthof. \"We expect to initiate our registrational Phase IIb/III study for Bipolar Depression in patients with acute suicidal ideation & behavior (ASIB) in the second half of this year with commercial level material.\" \nHaving an effective therapeutic for Critical COVID-19 is of the utmost importance, as the U.S. is still losing nearly 300 Americans to COVID-19 daily. ZYESAMI® is the only remaining drug for Critical COVID-19 in the NIH sponsored ACTIV-3b Trial. NRx Pharmaceuticals made important progress to further improve its proprietary formulation of aviptadil and has now achieved refrigerated stability of up to 8 months and expected multi-year frozen stability (-20°C).\nThough infections have gone down since earlier this year, the White House recently issued a warning of up to 100 million new infections in the fall and winter. For the ongoing ZYESAMI® NIH Phase III ACTIV-3b Trial, the next DSMB meeting is scheduled for May 25, 2022, instead of an originally planned meeting in April. The NIH ACTIV-3b Trial leadership indicated to NRx Pharmaceuticals that this new timing would allow th...

More updates from Nrx Pharmaceuticals, Inc.